Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® Disc Augmentation System: A Pilot Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Spinal Restoration, Inc.
ClinicalTrials.gov Identifier:
NCT00693784
First received: June 4, 2008
Last updated: August 31, 2011
Last verified: August 2011
  Purpose

The purpose of this study is to assess the safety of the Biostat Disc Augmentation System for the treatment of chronic low-back (lumbar) pain due to symptomatic internal disc disruptions (IDD) and to obtain preliminary efficacy information.


Condition Intervention
Low Back Pain
Other: Biostat® Disc Augmentation System

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter Pilot Study of Resorbable Biologic Disc Augmentation for Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® Disc Augmentation System

Resource links provided by NLM:


Further study details as provided by Spinal Restoration, Inc.:

Primary Outcome Measures:
  • Numbers and Types of Adverse Events (Only Number of Events is Reported in This Section - See Adverse Events Section for Further Detail) [ Time Frame: 104 weeks ] [ Designated as safety issue: Yes ]
    The primary outcome for this safety study includes the number and types of adverse events reported in the study. The data fields in this section do not allow for reporting all aspects of this outcome (i.e., the number of adverse events, as well as the types of event). These numbers were entered and are reported in the adverse event section of the Results.


Secondary Outcome Measures:
  • Visual Analog Scale for Low-back Pain [ Time Frame: Baseline, 26-weeks (primary endpoint), 52-weeks, 104-weeks ] [ Designated as safety issue: No ]
    100 mm line anchored on the left with the descriptor "No pain" (best value = 0 mm) and anchored on the right with the descriptor "Worst possible pain" (worst value = 100 mm). Lower scores indicate less pain.

  • Roland-Morris Disability Questionnaire [ Time Frame: Baseline, 26-weeks (primary endpoint), 52-weeks, 104-weeks ] [ Designated as safety issue: No ]
    24-item questionnaire with score determined by the number of items checked by the subject. Items assess the effect of back pain on limitations of normal daily activities. Best value = 0 (least disability). Worst value = 24 (most disability). Higher number indicate greater disability.


Enrollment: 15
Study Start Date: June 2008
Study Completion Date: January 2011
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Biostat® Disc Augmentation System
    Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
Detailed Description:

The Biostat Disc Augmentation System is a combination product combining a resorbable biologic product with a delivery device system used to prepare and insert the biologic material into a lumbar intervertebral disc.

Symptomatic IDD is defined as a painful disruption of the internal architecture of a lumbar intervertebral disc, which appears as fissures, cracks or tears within the internal structures of the disc. Pain arising from a lumbar disc may not only be perceived as pain located in the low back (axial pain), but also as somatic referred pain involving the posterior hips, buttock, lateral hips, groin, or posterior thighs.

The diagnosis of symptomatic IDD cannot currently be made on the basis of imaging studies, physical examination, or symptoms alone, and must be established with meticulously conducted disc provocation studies (provocation discography) that include pressure manometry, and identification of an adjacent normal disc.

This treatment and study are not designed for patients exhibiting other potential sources of chronic low back pain such as more advanced degenerative disc disease with significant loss of disc height (> 33%), spinal stenosis, or spondylolisthesis (see Eligibility Criteria).

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-75 (inclusive) and skeletally mature.
  • Voluntarily signs the subject informed consent form and agrees to the release of medical information for purposes of this study (HIPAA authorization).
  • Physically and mentally able to comply with the protocol, including ability to read and complete required forms, and willing and able to adhere to the follow-up requirements of the protocol.
  • Low-back pain for at least 6 months.
  • Pretreatment baseline low-back pain of at least 40 mm on a 100 mm visual analog scale.
  • Referred leg pain, if present, is of noncompressive origin and there are no clinical findings of radiculopathy.
  • Low-back pain is greater than leg pain (if present) as measured on a visual analog scale. If bilateral leg pain, back pain is greater than worst leg pain.
  • Low-back pain unresponsive to at least 6 weeks of nonoperative treatment, which may include bed rest, antiinflammatory and analgesic medications, chiropractic manipulations, acupuncture, massage, physical therapy or home-directed lumbar exercise program.
  • Negative response to diagnostic medial branch block or facet joint injection.
  • No sustained relief with epidural injection of corticosteroids.
  • Diagnosis of symptomatic lumbar (L1/L2-L5/S1) internal disc disruption (IDD), which requires confirmation of discogenic pain at one or two contiguous levels through positive provocation discography performed using pressure manometry and identification of an adjacent normal disc. The disc provocation studies must precisely demonstrate concordant pain (<50 psi above opening pressure) and must demonstrate a fissure(s) in the outer one-third of the posterior or lateral anulus.

Exclusion Criteria:

  • Cauda equina syndrome.
  • Active malignancy or tumor as source of symptoms.
  • Infection at the planned procedure site or active systemic infection.
  • Previous lumbar spine surgery.
  • Previous disc invasive treatment procedures at the affected level(s) (e.g., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation) in the past 12 months or intradiscal corticosteroid injection within the past 3 months.
  • Evidence of prior lumbar vertebral body fracture or trauma.
  • Disc bulge/protrusion at the symptomatic level(s) > 4 mm.
  • Presence of disc extrusion or sequestration.
  • Clinical findings of lumbosacral motor or sensory radiculopathy.
  • Leg pain is greater than low-back pain as measured on a visual analog scale.
  • Lumbar intervertebral foramen stenosis at the affected level(s) resulting in significant spinal nerve root compression or impingement.
  • Symptomatic central vertebral canal stenosis or absolute sagittal vertebral canal diameter < 9mm.
  • Loss of disc space height at the symptomatic level(s) greater than one-third of an adjacent normal disc (or of the expected height in the case of an L5-S1 disc).
  • Spondylolisthesis (≥ Grade 1) with or without spondylolysis at the symptomatic level(s).
  • Lumbar spondylitis or other undifferentiated spondyloarthropathy.
  • Dynamic instability on lumbar flexion-extension radiographs.
  • Positive response to diagnostic medial branch block or facet joint injection.
  • Positive response to diagnostic sacroiliac joint injection for those patients with pain in the sacral region
  • Sustained relief obtained with epidural injection of corticosteroids.
  • Symptomatic involvement of more than two lumbar disc levels.
  • Congenital or acquired coagulopathy or thrombocytopenia; or currently taking anticoagulant, antineoplastic, antiplatelet, or thrombocytopenia-inducing medications.
  • History of unexplained, easy, or persistent bruising or bleeding, bleeding from the gums, or bleeding problems experienced in previous surgical procedures.
  • Aspirin or aspirin-containing medication taken ≤7 days prior to the procedure.
  • Significant systemic disease, including unstable angina, autoimmune disease, rheumatoid arthritis, and muscular dystrophy.
  • Known or suspected hypersensitivity or allergy to drugs or components of the fibrin sealant, including aprotinin, used in the procedure.
  • History of, or current psychiatric condition, substance or alcohol abuse that would potentially interfere with the subject's participation in the study.
  • Ongoing or previous participation in another drug or device clinical study within the previous 2 months.
  • Subject known to be pregnant or nursing at time of enrollment or with plans to become pregnant within the planned length of follow-up (2 years).
  • Body habitus precludes adequate fluoroscopic visualization for the procedure or the procedure is physically impossible using the device.
  • Concomitant conditions requiring daily oral steroid usage for more than 30 days in the preceding 90 days.
  • Pending litigation against a health care professional, except where required by the insurer as a condition of coverage.
  • Prisoner or active military personnel who would not be available for follow-up.
  • Presence of ferromagnetic implants that would disallow MRI of the symptomatic disc(s).
  • Active or pending workers' compensation claims.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00693784

Locations
United States, Maryland
Bethesda, Maryland, United States, 20814
United States, Texas
Tyler, Texas, United States, 75701
United States, Washington
Bellingham, Washington, United States, 98226
Sponsors and Collaborators
Spinal Restoration, Inc.
Investigators
Principal Investigator: Kevin J Pauza, MD Spine Specialists, PA
  More Information

No publications provided

Responsible Party: Spinal Restoration, Inc.
ClinicalTrials.gov Identifier: NCT00693784     History of Changes
Other Study ID Numbers: SR-BX01P-2007
Study First Received: June 4, 2008
Results First Received: March 8, 2010
Last Updated: August 31, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Spinal Restoration, Inc.:
Intervertebral Disk
chronic low back pain
internal disc disruption
degenerative disc disease

Additional relevant MeSH terms:
Back Pain
Low Back Pain
Nervous System Diseases
Neurologic Manifestations
Pain
Signs and Symptoms

ClinicalTrials.gov processed this record on November 25, 2014